Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Humanized Mouse Model Market by Type (Cell-based Humanized Mouse Model, Genetic Humanized Mouse Model), by Application (Immunology Infectious Diseases, Neuroscience, Oncology, Hematopoiesis, Toxicology, Other Applications) and by End User (Contract Research Organizations (CROs), Pharmaceutical Biotechnology Companies, Academic Research Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02641

Pages: NA

Charts: NA

Tables: NA

Humanized mouse is a mouse that possesses functioning human genes, cells, tissues, and/or organs in case of biological and medical research for human therapeutics. These mouse models are used to model the human immune system in scenarios of health and pathology.

Usage of mouse models for identification of immunodeficiency disorders, cancers, and other rare diseases, increase in R&D activities carried out by pharmaceutical & biotechnology companies; continuous support & initiatives from governments & private sectors for research on mouse models; and growth in adoption of modified medicine increase the demand for personalized mouse models.

However, stringent regulations and laws formulated for ethical use of animals and costly procedures for maintenance of animal housing restrain the growth of the global humanized mouse model market. Increased production of monoclonal antibodies and improvement of healthcare in developing nations are expected to provide growth opportunities for the market.

The humanized mouse model is segmented on the basis of type, application, end user, and region. Based on type, the market is bifurcated into cell-based humanized mouse model and genetic humanized mouse model. Cell-based humanized mouse models segment is further classified into CD34, PBMC, and BLT. Applications covered in the study include immunology & infectious diseases, neuroscience, oncology, hematopoiesis, toxicology, and others.

By end user, the market is divided into contract research organizations (CROs), pharmaceutical & biotechnology companies, and academic & research institutes. Geographically, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Key players operating in the global humanized mouse model market include The Jackson Laboratory, Taconic Biosciences, Inc., Harbour BioMed, HuMurine Technologies, Inc., Vitalstar Biotechnology Co. Ltd., Crown Bioscience, Inc., ingenious targeting laboratory, Axenis S.A.S., TRANS GENIC, Inc., and genOway S. A.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • Comprehensive analysis of all geographical regions is provided, which helps to determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly, which help to understand competitive outlook of the global market.
  • The report offers a quantitative analysis which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Exhaustive analysis of the humanized mouse model market by type helps to understand the types of mouse that are currently being used along with the variants that are expected to gain prominence in the future.

 Key Market Segments

  • By Type
    • Cell-based Humanized Mouse Model
      • CD34
      • PBMC
      • BLT
    • Genetic Humanized Mouse Model
  • By Application
    • Immunology & Infectious Diseases
    • Neuroscience
    • Oncology
    • Hematopoiesis
    • Toxicology
    • Other Applications
  • By End User
    • Contract Research Organizations (CROs)
    • Pharmaceutical & Biotechnology Companies
    • Academic & Research Institutes
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • TRANS GENIC, Inc.
  • genOway S. A.
  • The Jackson Laboratory
  • Harbour BioMed
  • Axenis S.A.S.
  • Crown Bioscience Inc.
  • Taconic Biosciences, Inc.
  • Vitalstar Biotechnology Co. Ltd.
  • HuMurine Technologies, Inc.
  • Ingenious Targeting Laboratory

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: HUMANIZED MOUSE MODEL MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Cell-based Humanized Mouse Model

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. CD34

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. PBMC

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. BLT

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Genetic Humanized Mouse Model

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: HUMANIZED MOUSE MODEL MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Immunology And Infectious Diseases

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Neuroscience

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Oncology

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Hematopoiesis

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Toxicology

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Other Applications

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: HUMANIZED MOUSE MODEL MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Contract Research Organizations (CROs)

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Pharmaceutical And Biotechnology Companies

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Academic And Research Institutes

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: HUMANIZED MOUSE MODEL MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Type

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Humanized Mouse Model Market

        • 7.2.6.1. Market Size and Forecast, By Type
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Humanized Mouse Model Market

        • 7.2.7.1. Market Size and Forecast, By Type
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Humanized Mouse Model Market

        • 7.2.8.1. Market Size and Forecast, By Type
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Type

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Humanized Mouse Model Market

        • 7.3.6.1. Market Size and Forecast, By Type
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Humanized Mouse Model Market

        • 7.3.7.1. Market Size and Forecast, By Type
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Humanized Mouse Model Market

        • 7.3.8.1. Market Size and Forecast, By Type
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Humanized Mouse Model Market

        • 7.3.9.1. Market Size and Forecast, By Type
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Humanized Mouse Model Market

        • 7.3.10.1. Market Size and Forecast, By Type
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Humanized Mouse Model Market

        • 7.3.11.1. Market Size and Forecast, By Type
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Humanized Mouse Model Market

        • 7.3.12.1. Market Size and Forecast, By Type
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Type

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Humanized Mouse Model Market

        • 7.4.6.1. Market Size and Forecast, By Type
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Humanized Mouse Model Market

        • 7.4.7.1. Market Size and Forecast, By Type
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Humanized Mouse Model Market

        • 7.4.8.1. Market Size and Forecast, By Type
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Humanized Mouse Model Market

        • 7.4.9.1. Market Size and Forecast, By Type
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Humanized Mouse Model Market

        • 7.4.10.1. Market Size and Forecast, By Type
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Humanized Mouse Model Market

        • 7.4.11.1. Market Size and Forecast, By Type
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Humanized Mouse Model Market

        • 7.4.12.1. Market Size and Forecast, By Type
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Humanized Mouse Model Market

        • 7.4.13.1. Market Size and Forecast, By Type
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Humanized Mouse Model Market

        • 7.4.14.1. Market Size and Forecast, By Type
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Type

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Humanized Mouse Model Market

        • 7.5.6.1. Market Size and Forecast, By Type
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Humanized Mouse Model Market

        • 7.5.7.1. Market Size and Forecast, By Type
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Humanized Mouse Model Market

        • 7.5.8.1. Market Size and Forecast, By Type
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Humanized Mouse Model Market

        • 7.5.9.1. Market Size and Forecast, By Type
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Humanized Mouse Model Market

        • 7.5.10.1. Market Size and Forecast, By Type
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Humanized Mouse Model Market

        • 7.5.11.1. Market Size and Forecast, By Type
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. The Jackson Laboratory

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Taconic Biosciences, Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Harbour BioMed

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. HuMurine Technologies, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Vitalstar Biotechnology Co. Ltd.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Crown Bioscience Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Ingenious Targeting Laboratory

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Axenis S.A.S.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. TRANS GENIC, Inc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. GenOway S. A.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HUMANIZED MOUSE MODEL MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR CELL-BASED HUMANIZED MOUSE MODEL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR GENETIC HUMANIZED MOUSE MODEL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL HUMANIZED MOUSE MODEL MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR NEUROSCIENCE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR ONCOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR HEMATOPOIESIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR TOXICOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR OTHER APPLICATIONS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL HUMANIZED MOUSE MODEL MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL HUMANIZED MOUSE MODEL MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL HUMANIZED MOUSE MODEL MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA HUMANIZED MOUSE MODEL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. U.S. HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. U.S. HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. U.S. HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. CANADA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 24. CANADA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. CANADA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE HUMANIZED MOUSE MODEL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. ITALY HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ITALY HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. ITALY HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. UK HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 46. UK HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. UK HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC HUMANIZED MOUSE MODEL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. CHINA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. CHINA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. CHINA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. INDIA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. INDIA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. INDIA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA HUMANIZED MOUSE MODEL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 98. UAE HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 99. UAE HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 100. UAE HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA HUMANIZED MOUSE MODEL, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA HUMANIZED MOUSE MODEL, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA HUMANIZED MOUSE MODEL, BY END USER, 2025-2033 ($MILLION)
  • TABLE 107. THE JACKSON LABORATORY: KEY EXECUTIVES
  • TABLE 108. THE JACKSON LABORATORY: COMPANY SNAPSHOT
  • TABLE 109. THE JACKSON LABORATORY: OPERATING SEGMENTS
  • TABLE 110. THE JACKSON LABORATORY: PRODUCT PORTFOLIO
  • TABLE 111. THE JACKSON LABORATORY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. TACONIC BIOSCIENCES, INC.: KEY EXECUTIVES
  • TABLE 113. TACONIC BIOSCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 114. TACONIC BIOSCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 115. TACONIC BIOSCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 116. TACONIC BIOSCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. HARBOUR BIOMED: KEY EXECUTIVES
  • TABLE 118. HARBOUR BIOMED: COMPANY SNAPSHOT
  • TABLE 119. HARBOUR BIOMED: OPERATING SEGMENTS
  • TABLE 120. HARBOUR BIOMED: PRODUCT PORTFOLIO
  • TABLE 121. HARBOUR BIOMED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. HUMURINE TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 123. HUMURINE TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 124. HUMURINE TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 125. HUMURINE TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 126. HUMURINE TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. VITALSTAR BIOTECHNOLOGY CO. LTD.: KEY EXECUTIVES
  • TABLE 128. VITALSTAR BIOTECHNOLOGY CO. LTD.: COMPANY SNAPSHOT
  • TABLE 129. VITALSTAR BIOTECHNOLOGY CO. LTD.: OPERATING SEGMENTS
  • TABLE 130. VITALSTAR BIOTECHNOLOGY CO. LTD.: PRODUCT PORTFOLIO
  • TABLE 131. VITALSTAR BIOTECHNOLOGY CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. CROWN BIOSCIENCE INC.: KEY EXECUTIVES
  • TABLE 133. CROWN BIOSCIENCE INC.: COMPANY SNAPSHOT
  • TABLE 134. CROWN BIOSCIENCE INC.: OPERATING SEGMENTS
  • TABLE 135. CROWN BIOSCIENCE INC.: PRODUCT PORTFOLIO
  • TABLE 136. CROWN BIOSCIENCE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. INGENIOUS TARGETING LABORATORY: KEY EXECUTIVES
  • TABLE 138. INGENIOUS TARGETING LABORATORY: COMPANY SNAPSHOT
  • TABLE 139. INGENIOUS TARGETING LABORATORY: OPERATING SEGMENTS
  • TABLE 140. INGENIOUS TARGETING LABORATORY: PRODUCT PORTFOLIO
  • TABLE 141. INGENIOUS TARGETING LABORATORY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. AXENIS S.A.S.: KEY EXECUTIVES
  • TABLE 143. AXENIS S.A.S.: COMPANY SNAPSHOT
  • TABLE 144. AXENIS S.A.S.: OPERATING SEGMENTS
  • TABLE 145. AXENIS S.A.S.: PRODUCT PORTFOLIO
  • TABLE 146. AXENIS S.A.S.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. TRANS GENIC, INC.: KEY EXECUTIVES
  • TABLE 148. TRANS GENIC, INC.: COMPANY SNAPSHOT
  • TABLE 149. TRANS GENIC, INC.: OPERATING SEGMENTS
  • TABLE 150. TRANS GENIC, INC.: PRODUCT PORTFOLIO
  • TABLE 151. TRANS GENIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. GENOWAY S. A.: KEY EXECUTIVES
  • TABLE 153. GENOWAY S. A.: COMPANY SNAPSHOT
  • TABLE 154. GENOWAY S. A.: OPERATING SEGMENTS
  • TABLE 155. GENOWAY S. A.: PRODUCT PORTFOLIO
  • TABLE 156. GENOWAY S. A.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMANIZED MOUSE MODEL MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HUMANIZED MOUSE MODEL MARKET
  • FIGURE 3. SEGMENTATION HUMANIZED MOUSE MODEL MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HUMANIZED MOUSE MODEL MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHUMANIZED MOUSE MODEL MARKET
  • FIGURE 11. HUMANIZED MOUSE MODEL MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. HUMANIZED MOUSE MODEL MARKET FOR CELL-BASED HUMANIZED MOUSE MODEL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. HUMANIZED MOUSE MODEL MARKET FOR GENETIC HUMANIZED MOUSE MODEL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. HUMANIZED MOUSE MODEL MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. HUMANIZED MOUSE MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. HUMANIZED MOUSE MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. HUMANIZED MOUSE MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. HUMANIZED MOUSE MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. HUMANIZED MOUSE MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. HUMANIZED MOUSE MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. HUMANIZED MOUSE MODEL MARKET SEGMENTATION, BY BY END USER
  • FIGURE 22. HUMANIZED MOUSE MODEL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. HUMANIZED MOUSE MODEL MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. HUMANIZED MOUSE MODEL MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: HUMANIZED MOUSE MODEL MARKET
  • FIGURE 31. TOP PLAYER POSITIONING, 2024
  • FIGURE 32. THE JACKSON LABORATORY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. THE JACKSON LABORATORY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. THE JACKSON LABORATORY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. TACONIC BIOSCIENCES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. TACONIC BIOSCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. TACONIC BIOSCIENCES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. HARBOUR BIOMED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. HARBOUR BIOMED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. HARBOUR BIOMED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. HUMURINE TECHNOLOGIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. HUMURINE TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. HUMURINE TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. VITALSTAR BIOTECHNOLOGY CO. LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. VITALSTAR BIOTECHNOLOGY CO. LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. VITALSTAR BIOTECHNOLOGY CO. LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. CROWN BIOSCIENCE INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. CROWN BIOSCIENCE INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. CROWN BIOSCIENCE INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. INGENIOUS TARGETING LABORATORY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. INGENIOUS TARGETING LABORATORY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. INGENIOUS TARGETING LABORATORY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. AXENIS S.A.S.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. AXENIS S.A.S.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. AXENIS S.A.S.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. TRANS GENIC, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. TRANS GENIC, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. TRANS GENIC, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. GENOWAY S. A.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. GENOWAY S. A.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. GENOWAY S. A.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Humanized Mouse Model Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved